Table 5.
Serum CCL2 levels of the study subjects after removing patients 31 and 50 and adjusting the data for the covariates of gender and age
| Unadjusted Data (ANOVA) | Adjusted Data (ANCOVA) | |||||||
|---|---|---|---|---|---|---|---|---|
| Serum CCL2 (pg/ml) | Std Error | 95% CI | Estimated Serum CCL2 (pg/ml) | Std Error | 95% CI | |||
| Lower Limit | Upper Limit | Lower Limit | Upper Limit | |||||
| Unexposed (no apparent disease) | 275.2 | 18.3 | 239.3 | 311.2 | 305.5 | 24.2 | 256.0 | 351.1 |
| Possibly Exposed (no apparent disease) | 307.5 | 6.2 | 295.3 | 319.7 | 305.4 | 7.7 | 290.4 | 320.8 |
| Mesothelioma (stage 1 patients) | 289.9 | 33.8 | 223.5 | 356.4 | 275.7 | 41.1 | 195.0 | 356.5 |
| Mesothelioma (stage 2 patients) | 281.0 | 52.4 | 178.1 | 383.9 | 261.0 | 63.6 | 136.0 | 386.0 |
| Mesothelioma (stage 3 patients) | 402.7b | 32.5 | 338.9 | 466.5 | 471.4 | 38.1 | 396.4 | 546.3 |
| Mesothelioma (stage 4 patients) | 420.5a,c,d | 27.6 | 366.3 | 474.8 | 492.5b,c,d | 32.7 | 428.3 | 556.7 |
aDifferent from the Unexposed (no apparent disease) group at p < 0.001
bDifferent from the Unexposed (no apparent disease) group at p < 0.05
cDifferent from the Possibly Exposed (no apparent disease) group at p < 0.01
dDifferent from the Mesothelioma stage 1 patients group at p < 0.05